Nanoscope Therapeutics to Present at ARVO Annual Meeting

Nanoscope Therapeutics Inc., a clinical biotechnology firm focused on developing gene therapies for retinal degenerative diseases, has announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be highlighted in six presentations at the ARVO Annual Meeting. This event will be held from May 5-9, 2024, in Seattle. The company's management team will attend the conference and be available at booth #4620.

One of the key presentations, titled "Longitudinal BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase 2b/3 randomized, sham-controlled, patient- and assessor-masked clinical trial (RESTORE)," will be delivered by Dr. Allen C. Ho, Chief Medical Advisor, on May 6, 2024. This paper session will take place from 4:15 to 4:30 p.m. PT at the Seattle Convention Center's Arch Building, room 612.

Another notable presentation is "Test-retest Agreement of the Freiburg Visual Acuity Test in Ultra-low Vision," which will be presented by Dr. Samuel Barone, Chief Medical Officer, on May 7, 2024. This poster session will be held from 1:15 to 3:00 p.m. PT in the Exhibit Hall of the Seattle Convention Center.

Additionally, Dr. Vinit B. Mahajan, a professor of ophthalmology at Stanford University, will present "Longitudinal BCVA Analysis of Patients with Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT)" on May 8, 2024. This poster session will take place from 2:15 to 4:00 p.m. PT in the same location.

Dr. Subrata Batabyal, Director of Non-Clinical Development, is scheduled to present "Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in mouse models of retinitis pigmentosa" on May 8, 2024. This session will also be held from 2:15 to 4:00 p.m. PT in the Exhibit Hall of the Seattle Convention Center.

Another presentation, "Characterization of a Broadband Ambient Light Activatable Multi-Characteristic Opsin Supporting its Superior Performance in Restoring Vision," will be delivered by Dr. Samarendra Mohanty, President and Chief Scientific Officer, on May 9, 2024. This poster session is set to occur from 8:00 to 9:45 a.m. PT in the Exhibit Hall.

Lastly, Dr. Najam Sharif, Vice President of Global Research and Development, will present "In Vivo Efficacy of a Novel Multi-Characteristic Opsin (MCO-010) in a Mouse Model of Leber Congenital Amaurosis" on May 9, 2024. This session will be from 8:00 to 9:45 a.m. PT in the Exhibit Hall of the Seattle Convention Center.

Nanoscope Therapeutics is committed to developing gene-agnostic, sight-restoring optogenetic therapies for patients suffering from inherited retinal diseases who currently have no cure. The company's lead product, MCO-010, has shown promising results in the RESTORE Phase 2b/3 clinical trial for retinitis pigmentosa and the Phase 2 STARLIGHT trial for Stargardt disease. MCO-010 has received FDA fast-track and orphan drug designations for both conditions. The company's preclinical initiatives include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to age-related macular degeneration.